157 related articles for article (PubMed ID: 37137809)
21. Cost-effectiveness of pembrolizumab for treatment of platinum-resistant recurrent or metastatic head and neck squamous cell carcinoma in China: an economic analysis based on a randomised, open-label, phase III trial.
Xin W; Ding H; Fang Q; Zheng X; Tong Y; Xu G; Yang G
BMJ Open; 2020 Dec; 10(12):e038867. PubMed ID: 33371020
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
23. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients.
Mojtahed SA; Boyer NR; Rao SA; Gajewski TF; Tseng J; Turaga KK
Ann Surg Oncol; 2021 Dec; 28(13):9039-9047. PubMed ID: 34129153
[TBL] [Abstract][Full Text] [Related]
24. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
[TBL] [Abstract][Full Text] [Related]
26. Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Powles T; Tomczak P; Park SH; Venugopal B; Ferguson T; Symeonides SN; Hajek J; Gurney H; Chang YH; Lee JL; Sarwar N; Thiery-Vuillemin A; Gross-Goupil M; Mahave M; Haas NB; Sawrycki P; Burgents JE; Xu L; Imai K; Quinn DI; Choueiri TK;
Lancet Oncol; 2022 Sep; 23(9):1133-1144. PubMed ID: 36055304
[TBL] [Abstract][Full Text] [Related]
27. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness Analysis of Pembrolizumab in Patients With Advanced Esophageal Cancer Based on the KEYNOTE-181 Study.
Zhan M; Xu T; Zheng H; He Z
Front Public Health; 2022; 10():790225. PubMed ID: 35309225
[TBL] [Abstract][Full Text] [Related]
29. Cost-effectiveness of Pembrolizumab as Second-line Therapy for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma in Sweden.
Srivastava T; Prabhu VS; Li H; Xu R; Zarabi N; Zhong Y; Pellissier JM; Perini RF; de Wit R; Mamtani R
Eur Urol Oncol; 2020 Oct; 3(5):663-670. PubMed ID: 31412001
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma.
Zhu J; Zhang T; Wan N; Liang Z; Li J; Chen X; Liang W; Jiang J
Immunotherapy; 2020 Dec; 12(17):1237-1246. PubMed ID: 32878521
[No Abstract] [Full Text] [Related]
32. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness and budget impact of pembrolizumab+axitinib versus sunitinib in patients with advanced clear-cell renal cell carcinoma in the Netherlands.
Xander NSH; Fiets WE; Uyl-de Groot CA
Front Oncol; 2023; 13():1205700. PubMed ID: 37448519
[TBL] [Abstract][Full Text] [Related]
35. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer.
Aziz MIA; Tan LE; Tan WHG; Toh CK; Loke LPY; Pearce F; Ng K
J Med Econ; 2020 Sep; 23(9):952-960. PubMed ID: 32462958
[No Abstract] [Full Text] [Related]
37. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
38. Economic evaluation of first-line nivolumab plus cabozantinib for advanced renal cell carcinoma in China.
Wang H; Wang Y; Li L; Zhou H; Lili S; Li L; Yike S; Aixia M
Front Public Health; 2022; 10():954264. PubMed ID: 36159269
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness analysis of nivolumab plus cabozantinib versus sunitinib as first-line therapy in advanced renal cell carcinoma.
Liu R; Qiu K; Wu J; Jiang Y; Wu P; Pang J
Immunotherapy; 2022 Aug; 14(11):859-869. PubMed ID: 35754404
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]